He pumped thousands into a SpaceX fund before it went public. But when the trading began, his dream of a windfall turned into a nightmare. https://t.co/xLZl6wx0tR
For years, Chinese companies such as Alibaba and Baidu headed to the U.S. to list their shares, citing its deeper capital markets and higher valuations. Now, one American biotech firm is betting on doing the opposite.
Axiom Biosciences, a San Diego-based developer of regenerative and genetic medicines, plans to go public in Hong Kong in 2027, followed by a secondary U.S. listing in 2029.
Click here to read more: https://t.co/cXW0LtYsGC